Amount and distribution of dietary protein affects clinical response to levodopa in Parkinson's disease
- PMID: 2648188
- DOI: 10.1212/wnl.39.4.552
Amount and distribution of dietary protein affects clinical response to levodopa in Parkinson's disease
Abstract
Reducing dietary protein improves the effectiveness of levodopa (LD) but the most effective distribution of a low-protein diet (0.8 g/kg) is unclear. We compared a 1.6 g/kg protein diet, a 0.8 g/kg diet with protein evenly distributed between meals, and a 0.8 g/kg diet with protein restricted to the evening meal in 5 parkinsonian patients with motor fluctuations. We monitored clinical response, plasma LD, and plasma large amino acids (LNAAs) hourly throughout the day. Mean "on" times were 51% (1.6 g/kg diet), 67% (0.8 g/kg evenly distributed), and 77% (0.8 g/kg restricted). Hourly averages of plasma LD did not differ between the diets. The mean plasma LNAAs were 732 nmol/ml (1.6 g/kg diet), 640 (0.8 g/kg distributed), and 542 (0.8 g/kg restricted), and the diurnal pattern reflected the distribution of protein intake. In conclusion, the amount and distribution of dietary protein affect clinical response to LD. These effects are not related to LD absorption but are explained by the variation in plasma LNAAs.
Similar articles
-
Influence of fluctuations of plasma large neutral amino acids with normal diets on the clinical response to levodopa.J Neurol Neurosurg Psychiatry. 1989 Apr;52(4):481-7. doi: 10.1136/jnnp.52.4.481. J Neurol Neurosurg Psychiatry. 1989. PMID: 2738591 Free PMC article.
-
Dietary influences on the antiparkinsonian response to levodopa.Arch Neurol. 1987 Oct;44(10):1003-5. doi: 10.1001/archneur.1987.00520220009006. Arch Neurol. 1987. PMID: 3632369
-
Dietary method for reducing fluctuations in Parkinson's disease.Yale J Biol Med. 1987 Mar-Apr;60(2):133-7. Yale J Biol Med. 1987. PMID: 3577210 Free PMC article.
-
IPX066: a novel carbidopa-levodopa extended-release formulation.Expert Rev Neurother. 2012 Feb;12(2):133-40. doi: 10.1586/ern.11.195. Expert Rev Neurother. 2012. PMID: 22288668 Review.
-
Pharmacokinetic considerations for the use of levodopa in the treatment of Parkinson disease: focus on levodopa/carbidopa/entacapone for treatment of levodopa-associated motor complications.Clin Neuropharmacol. 2013 May-Jun;36(3):84-91. doi: 10.1097/WNF.0b013e31828f3385. Clin Neuropharmacol. 2013. PMID: 23673910 Review.
Cited by
-
Using liquid levodopa in the treatment of Parkinson's disease. A practical guide.Drugs Aging. 1997 May;10(5):332-40. doi: 10.2165/00002512-199710050-00002. Drugs Aging. 1997. PMID: 9143854 Review.
-
The gut-brain axis and Parkinson disease: clinical and pathogenetic relevance.Ann Med. 2021 Dec;53(1):611-625. doi: 10.1080/07853890.2021.1890330. Ann Med. 2021. PMID: 33860738 Free PMC article. Review.
-
The influence of protein containing meals on the pharmacokinetics of levodopa in healthy volunteers.Br J Clin Pharmacol. 1991 Apr;31(4):413-7. doi: 10.1111/j.1365-2125.1991.tb05555.x. Br J Clin Pharmacol. 1991. PMID: 2049250 Free PMC article. Clinical Trial.
-
Long-term Medical Treatment for Parkinson's Disease.Curr Treat Options Neurol. 2001 Nov;3(6):495-506. doi: 10.1007/s11940-001-0012-y. Curr Treat Options Neurol. 2001. PMID: 11581526
-
Levodopa-induced response fluctuations in patients with Parkinson's disease: strategies for management.CNS Drugs. 2003;17(7):475-89. doi: 10.2165/00023210-200317070-00002. CNS Drugs. 2003. PMID: 12751918 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials